Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest: A Phase III Multi-Centre Randomised Controlled Trial (The TAME Cardiac Arrest Trial)

驯服心脏骤停试验将研究更高的二氧化碳（CO2）水平减少脑损伤的能力，比较给予患者“正常”和“略高于正常”的血液CO2水平，并评估他们恢复正常生活任务的能力。这将是有史以来在ICU心脏病发作患者中进行的最大规模的试验。这种疗法是免费的，如果证明是有效的，将改善成千上万的澳大利亚人的生活，改变临床实践，并产生重大储蓄。

The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.